Immune thrombocytopenia (ITP) remains therapeutically challenging in patients with refractory or relapsed disease despite expanding second-line options. Increasing evidence implicates autoreactive plasma cells in treatment resistance, providing a rationale for... ...

请注册登录后继续浏览